Literature DB >> 27467941

Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma.

Olli Helminen1, Heikki Huhta1, Petri P Lehenkari2, Juha Saarnio3, Tuomo J Karttunen4, Joonas H Kauppila1.   

Abstract

Toll-like receptors (TLRs) are immunological receptors recognizing various microbial and endogenous ligands, such as DNA, RNA, and other microbial and host components thus activating immunological responses. The expression of TLRs in esophageal adenocarcinoma is not well known. The aim of this study was to evaluate expression patterns of those TLRs that sense nucleic acids in Barrett's esophagus with and without dysplasia and in esophageal adenocarcinoma. TLRs 3, 7 and 8 were stained immunohistochemically and evaluated in a cohort of patients with esophageal adenocarcinoma or dysplasia. Specimens with normal esophagus (n = 88), gastric (n = 67) or intestinal metaplasia (n = 51) without dysplasia, and low-grade (n = 42) or high-grade dysplasia (n = 37) and esophageal adenocarcinoma (n = 99) were studied. We used immunofluorescence to confirm the subcellular localization of TLRs. We found abundant expression of TLR3, 7 and 8 in esophageal squamous epithelium, columnar metaplasia, dysplasia and adenocarcinoma. Cytoplasmic expression of TLR3, TLR7 or TLR8 did not associate to clinicopathological parameters or prognosis in esophageal cancer. High nuclear expression of TLR8, confirmed with immunofluorescence, in cancer cells was observed in tumors of high T-stage (p < 0.01) and in tumors with organ metastasis (p < 0.001). High nuclear TLR8 expression was associated with poor prognosis (p < 0.001). The expression of TLR3, TLR7 and TLR8 increased toward dysplasia and adenocarcinoma. We demonstrated nuclear localization of TLR8, which associates with metastasis and poor prognosis. TLR3 and TLR7 do not seem to have prognostic significance in esophageal adenocarcinoma.

Entities:  

Keywords:  Barrett’s esophagus; esophageal adenocarcinoma; esophageal cancer; toll-like receptor 3; toll-like receptor 7; toll-like receptor 8

Year:  2016        PMID: 27467941      PMCID: PMC4910747          DOI: 10.1080/2162402X.2015.1127495

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  24 in total

Review 1.  Antiviral signaling through pattern recognition receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  J Biochem       Date:  2006-12-26       Impact factor: 3.387

2.  Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer.

Authors:  Belen Fernandez-Garcia; Noemí Eiró; Salomé González-Reyes; Lucía González; Alina Aguirre; Luis O González; José M Del Casar; José L García-Muñiz; Francisco J Vizoso
Journal:  J Immunother       Date:  2014 Feb-Mar       Impact factor: 4.456

3.  Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines.

Authors:  Akiko Uehara; Yukari Fujimoto; Koichi Fukase; Haruhiko Takada
Journal:  Mol Immunol       Date:  2007-04-02       Impact factor: 4.407

4.  Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma.

Authors:  Ilyar Sheyhidin; Gulnaz Nabi; Ayshamgul Hasim; Rui-Ping Zhang; Julaiti Ainiwaer; Hong Ma; Hua Wang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

5.  Toll-like receptor 3 signaling enables human esophageal epithelial cells to sense endogenous danger signals released by necrotic cells.

Authors:  Diana M Lim; Mei-Lun Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-04-07       Impact factor: 4.052

6.  MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response.

Authors:  Muller Fabbri; Alessio Paone; Federica Calore; Roberta Galli; Eugenio Gaudio; Ramasamy Santhanam; Francesca Lovat; Paolo Fadda; Charlene Mao; Gerard J Nuovo; Nicola Zanesi; Melissa Crawford; Gulcin H Ozer; Dorothee Wernicke; Hansjuerg Alder; Michael A Caligiuri; Patrick Nana-Sinkam; Danilo Perrotti; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

7.  The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells.

Authors:  Lei Li; Feng-Wei Cheng; Fang Wang; Bo Jia; Xin Luo; Sheng-Quan Zhang
Journal:  Mol Cell Biochem       Date:  2013-12-18       Impact factor: 3.396

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Toll-like receptors in esophageal cancer.

Authors:  Joonas H Kauppila; Katri S Selander
Journal:  Front Immunol       Date:  2014-05-07       Impact factor: 7.561

View more
  10 in total

1.  Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.

Authors:  Olli Helminen; Heikki Huhta; Joni Leppänen; Joonas H Kauppila; Heikki Takala; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2016-07-09       Impact factor: 4.064

Review 2.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

3.  Direct and Intestinal Epithelial Cell-Mediated Effects of TLR8 Triggering on Human Dendritic Cells, CD14+CD16+ Monocytes and γδ T Lymphocytes.

Authors:  Costanza Angelini; Barbara Varano; Patrizia Puddu; Maurizio Fiori; Antonella Baldassarre; Andrea Masotti; Sandra Gessani; Lucia Conti
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

4.  Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma.

Authors:  Heikki Huhta; Olli Helminen; Sami Palomäki; Joonas H Kauppila; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  Oncotarget       Date:  2017-04-04

5.  TLR3 Expression is a Potential Prognosis Biomarker and Shapes the Immune-Active Tumor Microenvironment in Esophageal Squamous Cell Carcinoma.

Authors:  Ruibing Su; Lijun Cai; Pan Xiong; Zhiwei Liu; Shaobin Chen; Xi Liu; Runhua Lin; Zhijin Lei; Dongping Tian; Min Su
Journal:  J Inflamm Res       Date:  2022-02-28

Review 6.  Bacterial Translocation in Gastrointestinal Cancers and Cancer Treatment.

Authors:  Keita Kouzu; Hironori Tsujimoto; Yoji Kishi; Hideki Ueno; Nariyoshi Shinomiya
Journal:  Biomedicines       Date:  2022-02-04

7.  The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Tuula Salo; Katja Porvari; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

8.  Tenascin-C and fibronectin in normal esophageal mucosa, Barrett's esophagus, dysplasia and adenocarcinoma.

Authors:  Joni Leppänen; Sara Bogdanoff; Petri P Lehenkari; Juha Saarnio; Joonas H Kauppila; Tuomo J Karttunen; Heikki Huhta; Olli Helminen
Journal:  Oncotarget       Date:  2017-07-12

9.  Identification of prognostic genes and tumor-infiltrating immune cells in the tumor microenvironment of esophageal squamous cell carcinoma and esophageal adenocarcinoma.

Authors:  Qilin Huai; Wei Guo; Liankui Han; Demiao Kong; Liang Zhao; Peng Song; Yue Peng; Shugeng Gao
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

10.  Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.

Authors:  Shajan Peter; Amanda Pendergraft; William VanDerPol; C Mel Wilcox; Kondal R Kyanam Kabir Baig; Casey Morrow; Jacques Izard; Peter J Mannon
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.